Appendix Table C15. Survival and local control outcomes of studies that address Key Question 3

| Study | Survival Outcomes for Intervention Group 1 | Survival Outcomes for Intervention Group 2 | Local Control Outcomes for Intervention Group 1 | Local Control Outcomes for Intervention Group 2 | Arm |
| --- | --- | --- | --- | --- | --- |
| Allison-2004, #108 | **Overall survival:**  10.3 months (±4.1) (calculated)  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  100 %. No patient had local recurrence till they all died. However, mean or median FU time not reported. | **Local control:**  NA | No |
| Chella-2000, #654 | YAGL + BCHY  **Overall survival:**  Median survival: 10.3 months (method Not reported)  **Cancer/disease specific survival:**  Not reported | YAGL  **Overall survival:**  Median survival: 7.4 months (method Not reported)  **Cancer/disease specific survival:**  Not reported | YAGL + BCHY  **Local control:**  Not reported | YAGL  **Local control:**  Not reported | No |
| Celebioglu-2002, #604 | **Overall survival:**  Not reported  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | No |
| Celikoglu-2006, #606 | **Overall survival:**  Not reported  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  Not reported | No |
| Chhajed-2006, #696 | STNT or LASR:  **Overall survival:**  Median survival : 8.4 months (4.8-17.1),  3-months survival: 90%  6-months survival: 71%  12-months survival: 40%  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  9 patients had tumor growth. Thus local control was 87% (at unspecified time, assumption at the time of study closeout, average FU period not given) | **Local control:**  NA | Yes |
| Guilcher-2011, #188 | **Overall survival:**  Median survival: 28.6 months  2 yr: 57%  5 yr: 29%  **Cancer/disease specific survival:**  2 yr: 81%  5 yr: 56% | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  G3data | **Local control:**  NA | No |
| Jimenez-1999, #978 | PHDT:  **Overall survival:**  Median survival:  265 days  **Cancer/disease specific survival:**  Not reported | YAGL:  **Overall survival:**  Median survival  95 days (p=0.007)  **Cancer/disease specific survival:**  Not reported | PHDT:  **Local control:**  Not reported | YAGL:  **Local control:**  Not reported | No |
| Jones-2001, ,#1862 | **Overall survival:**  Mean survival:  From diagnosis: 10.5 months  Post PHDT Rx: 5.5 months  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | No |
| Langendjik-2001, #2144 | EBRT +BCHY:  **Overall survival:**  Median survival: 7.0 months (95%CI: 5.3 to 8.9)  **Cancer/disease specific survival:**  Not reported | EBRT:  **Overall survival:**  Median survival: 8.5 months (95%CI: 5.4 to 11.6)  **Cancer/disease specific survival:**  Not reported | EBRT +BCHY:  **Local control:**  Not reported | EBRT:  **Local control:**  Not reported | No |
| Lencioni-2008, #2238 | **Overall survival:**  1 yr: 70% (95% CI: 51 to 83)  2 yr: 48% (95% CI: 30 to 65)  **Cancer/disease specific survival:**  1 yr: 92% (95% CI: 78–98)  2 yr: 73% (95% CI: 54–86) | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | Yes |
| Moghissi-1999, #2591 | EBRT:  **Overall survival:**  Median survival: 182 days  1 yr survival: 26%  **Cancer/disease specific survival:**  Not reported | EBHT:  **Overall survival:**  Median survival: 150 days  1 yr survival: 29%  **Cancer/disease specific survival:**  Not reported | **Local control:**  Not reported | **Local control:**  Not reported | No |
| Muto-2000, Italy, #2665 | **Overall survival:**  Mean survival from diagnosis: 11.1 months  Mean survival from last HDR BCHY Rx: 9.7 months  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | No |
| Mallick-2006, #2417 | **Overall survival:** Not reported  **Cancer/disease specific survival:** Not reported | **Overall survival:** Not reported  **Cancer/disease specific survival:** Not reported | **Local control:** Not reported | **Local control:** Not reported | No |
| Petera-2001, #2914 | **Overall survival:**  Median survival (from diagnosis)  BCHY (Cur): 365 days (92-670)  BCHY (Pall): 242 days (30-881)  Median survival ( 1st BCHY Rx)  BCHY (Cur): 245 days (1-396)  BCHY (Pall): 242 days (1-850)  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  Not reported | **Local control:**  Not reported | **Local control:**  NA | Yes |
| Stout-2000, #3640 | BCHY:  **Overall survival:**  Median: 250 days  1 yr: 22%  2 yr: 2%  **Cancer/disease specific survival:**  Not reported | EBRT:  **Overall survival:**  Median: 287 days (p=0.042)  1 yr: 38%  2 yr: 10%  **Cancer/disease specific survival:**  Not reported | **Local control:**  Not reported | **Local control:**  Not reported | No |
| van Boxem-1999, #427 | **Overall survival:**  YAGL: 8.0 ± 2.5 m  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  ECAU: 11.5 ± 3.5 m  **Cancer/disease specific survival:**  Not reported | **Local control:**  Not reported | **Local control:**  Not reported | No |
| Vucicevic-1999, #4010 | **Overall survival:**  G3 data  Fig 5 page 380  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | No |
| Weinberg-2010, #4066 | **Overall survival:**  Consult TR Page 54 table 2  **Cancer/disease specific survival:**  Not reported | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  Not reported | **Local control:**  NA | No |